| Literature DB >> 29922848 |
Barbara Pisano Messing1,2,3, Elizabeth C Ward4,5, Cathy Lazarus6, Keri Ryniak7, Melissa Kim7, Jessica Silinonte7, Dorothy Gold7, Carol B Thompson8, Karen T Pitman7,9, Ray Blanco7, Ryan Sobel7, Karen Harrer7, Karen Ulmer7, Geoffrey Neuner7, Kruti Patel7, Mei Tang7, Gregory Lee7.
Abstract
Head and neck cancer (HNC) guidelines recommend regular multidisciplinary team (MDT) monitoring and early intervention to optimize dysphagia outcomes; however, many factors affect the ability to achieve these goals. The aims of this study were to explore the barriers/facilitators to establishing and sustaining a MDT HNC care pathway and to examine the dysphagia-related speech-language pathology (SLP) and dietetic components of the pathway. Using the Consolidated Framework for Implementation Research (CFIR), a mixed methods study design was used to evaluate an established MDT HNC pathway. Ten MDT members provided perceptions of facilitators/barriers to implementing and sustaining the pathway. Patients attending the SLP and dietetic components of the pathway who commenced treatment between 2013 and 2014 (n = 63) were audited for attendance, outcome data collected per visit, and swallowing outcomes to 24-month post-treatment. Dysphagia outcomes were compared to a published cohort who had received intensive prophylactic dysphagia management. Multiple CFIR constructs were identified as critical to implementing and sustaining the pathway. Complexity was a barrier. Patient attendance was excellent during treatment, with low rates of non-compliance (< 15%) to 24 months. Collection of clinician/patient outcome tools was good during treatment, but lower post-treatment. Dysphagia outcomes were good and comparable to prior published data. The pathway provided patients with access to regular supportive care and provided staff opportunities to provide early and ongoing dysphagia monitoring and management. However, implementing and sustaining a HNC pathway is complex, requiring significant staff resources, financial investment, and perseverance. Regular audits are necessary to monitor the quality of the pathway.Entities:
Keywords: Clinical pathway; Deglutition; Deglutition disorders; Dysphagia; Head and neck cancer; Implementation; Nutrition; Oral intake
Mesh:
Year: 2018 PMID: 29922848 PMCID: PMC6349813 DOI: 10.1007/s00455-018-9917-4
Source DB: PubMed Journal: Dysphagia ISSN: 0179-051X Impact factor: 3.438
Fig. 1Dance Head and Neck Clinical Pathway (D-HNCP) implementation timeline
Fig. 2Overview of Dance Head and Neck Clinical Pathway (D-HNCP) key time points from baseline to post-treatment for multidisciplinary team (MDT). [REDCap (Research Electronic Data Capture), NCCN National Comprehensive Cancer Network® (NCCN®)]
Routine data collection and time points for speech pathology and dietetic contact within the D-HNCP
| Outcome Measures | Pre-treatment | Week 1 | Week 3/4 | Months post CRT | ||||
|---|---|---|---|---|---|---|---|---|
| 1 | 3 | 6 | 12 | 24 | ||||
| Dietetics | ||||||||
| Weight | x | x | x | x | x | x | x | x |
| Presence and use of non-oral feeding | x | x | x | x | x | x | x | x |
| Speech language pathology | ||||||||
| Oral motor examinationb | x | x | x | x | x | |||
| Incisal openingc | x | x | x | x | x | x | x | |
| Maximal lingual pressured | x | x | x | x | x | |||
| Performance status scale (PSS)e | x | x | x | x | x | x | x | x |
| Functional oral intake score (FOIS)f | x | x | x | x | x | |||
| Modified barium swallow | x | x | x | |||||
| EAT-10g | x | x | x | x | x | x | x | x |
| EORTC C30 and HN35h | x | x | x | |||||
| Sydney swallow questionnaire (SSQ)i | x | x | x | x | x | |||
Exceptions to the Dance Head & Neck Clinical Pathway (D-HNCP): (a) patients undergoing extensive reconstructions do not complete a pre-treatment MBS, (b) patients receiving transoral robotic surgery (TORS) complete 2 additional contacts at day 1–3 and 2 weeks post TORS during which all assessments are completed except quality of life and an endoscopic assessment is completed instead of a MBS
aChemoradiation treatment (CRT)
bOral Motor Examination: as measured using the Milton J., Dance, Jr. Head & Neck Center Rating of Oral Motor Tool [25]
cIncisal opening: as measured using the Therabite® measuring tool
dIOPI: as measured using the Iowa oral pressure instrument (IOPI)
ePerformance status scale (PSS) [26]
fFunctional oral intake (FOIS) [27]
gEAT-10 [28]: patient-reported swallow outcome
hEuropean Organization for Research and Treatment of Cancer (EORTC QLQ-C30) and the Head and Neck Cancer Quality of Life module (EORTC QLQ-HN35) [29, 30]
iSydney Swallow Questionnaire (SSQ) [31]
Fig. 3Multidisciplinary team patient care plan. GBMC Greater Baltimore Medical Center
Perceived influence of CFIR domains and constructs for establishing and sustainability of the D-HNCP
| Establishing the D-HNCP ( | Sustainability of the D-HNCP ( | |||||
|---|---|---|---|---|---|---|
| Facilitator % | Barrier % | Low-impact/non-applicable % | Facilitator % | Barrier % | Low-impact/non-applicable% | |
| Intervention characteristics | ||||||
| Intervention source | 90 | 0 | 10 | 60 | 0 | 40 |
| Evidence strength and quality | 80 | 0 | 20 | 90 | 0 | 10 |
| Relative advantage | 90 | 0 | 10 | 70 | 0 | 30 |
| Adaptability | 100 | 0 | 0 | 80 | 10 | 10 |
| Trial ability | 90 | 0 | 10 | 90 | 0 | 10 |
| Complexity | 30 | 60 | 10 | 10 | 60 | 30 |
| Design quality and packaging | 40 | 30 | 30 | 40 | 30 | 30 |
| Cost | 20 | 30 | 50 | 0 | 30 | 70 |
| Outer setting | ||||||
| Patient needs and resources | 90 | 10 | 0 | 80 | 20 | 0 |
| Peer pressure | 10 | 20 | 70 | 20 | 10 | 70 |
| External policy and incentives | 10 | 10 | 80 | 10 | 20 | 70 |
| Inner setting | ||||||
| Structural characteristics | 70 | 0 | 30 | 70 | 0 | 30 |
| Networks and communications | 90 | 0 | 10 | 80 | 10 | 10 |
| Culture | 90 | 0 | 10 | 90 | 0 | 10 |
| Implementation climate | 90 | 10 | 0 | 80 | 20 | 0 |
| Tension for change | 0 | 20 | 80 | 0 | 40 | 60 |
| Compatibility | 80 | 10 | 10 | 90 | 10 | 0 |
| Relative priority | 80 | 10 | 10 | 90 | 10 | 0 |
| Organizational incentives and rewards | 10 | 10 | 80 | 10 | 10 | 80 |
| Goals and feedback | 100 | 0 | 0 | 90 | 0 | 10 |
| Learning climate | 90 | 10 | 0 | 90 | 10 | 0 |
| Readiness for implementation | 100 | 0 | 0 | 100 | 0 | 0 |
| Leadership engagement | 70 | 10 | 20 | 80 | 10 | 10 |
| Available resources | 100 | 0 | 0 | 90 | 10 | 0 |
| Access to knowledge and information | 80 | 20 | 0 | 90 | 10 | 0 |
| Process | ||||||
| Planning | 100 | 0 | 0 | 90 | 10 | 0 |
| Engaging | 80 | 20 | 0 | 70 | 30 | 0 |
| Opinion leaders | 100 | 0 | 0 | 70 | 20 | 10 |
| Formally appointed internal implementation leaders | 70 | 20 | 10 | 70 | 20 | 10 |
| Overall championing | 80 | 10 | 10 | 70 | 30 | 0 |
| External change agents | 40 | 0 | 60 | 40 | 0 | 60 |
Bold = 60% or more identified a construct as a facilitator or barrier
Patient and tumor characteristics of total D-HNCP cohort, the subgroup of chemoradiation therapy (CRT) patients in the D-HNCP and the reference research cohort [25]
| Characteristics | Total D-HNCP cohort | CRT cohort only | ||
|---|---|---|---|---|
| D-HNCP CRT cohort | Reference research cohort | |||
| Age at enrollmenta | ||||
| Median (IQR) | 62 (13) | 65 (10) | 55.5 (11) | < 0.001 |
| Min–max (range) | 44–81 (37) | 49–81 (32) | 44–78 (34) | |
| Genderb: male, | 64 (87.0%) | 36 (83.7%) | 28 (93.3%) | 0.195 |
| Tumor histology | ||||
| Squamous cell carcinoma | 43 (100%) | 30 (100%) | n/a | |
| Tumor locationc, | 0.487 | |||
| Larynx, hypopharynx, nasopharynx | 14 (19.2%) | 8 (18.6%) | 6 (20.0%) | |
| Oropharynx | 57 (78.1%) | 33 (76.7%) | 24 (80.0%) | |
| Unknown primary | 2 (2.7%) | 2 (4.7%) | 0 | |
| Overall stagec | 0.025 | |||
| 2 | 2 (2.7%) | 0 | 2 (6.7%) | |
| 3 | 14 (19.2%) | 5 (11.6%) | 9 (30.0%) | |
| 4, 4a, 4b | 57 (78.1%) | 38 (88.4%) | 19 (63.3%) | |
| T stagec | 0.046 | |||
| 0–1 | 13 (17.8%) | 9 (20.9%) | 4 (13.3%) | |
| 2 | 33 (45.2%) | 22 (51.2%) | 11 (36.7%) | |
| 3 | 17 (23.3%) | 5 (11.6%) | 12 (40.0%) | |
| 4 | 10 (13.7%) | 7 (16.3%) | 3 (10.0%) | |
| N stagec | 0.227 | |||
| 0–1 | 19 (26.0%) | 8 (18.6%) | 11 (36.7%) | |
| 2a, 2b | 37 (50.7%) | 25 (58.1%) | 12 (40.0%) | |
| 2c | 14 (19.2%) | 9 (20.9%) | 5 (16.7%) | |
| 3, 3b | 3 (4.1%) | 1 (2.3%) | 2 (6.7%) | |
| M stage | n/a | |||
| 0 | 73 (100%) | 43 (100%) | 30 (100%) | |
| 1 | 0 | 0 | 0 | |
Bolded values indicate p < 0.05
IQR interquartile range
aMann–Whitney test (non-parametric)
bFisher’s exact test
cPearson Chi-Square test
Fig. 4Audit of the Dance Head and Neck Clinical Pathway (D-HNCP): adherence 2013–2014 during and post-treatment
Fig. 5Audit of the Dance Head and Neck Clinical Pathway (D-HNCP) cohort: completion of 2013–2014 PROs/CROs during and post-treatment
Analysisa of swallowing outcomes of the chemoradiation therapy (CRT) patients in the D-HNCP cohort (n = 43) and the reference research sample [25] (n = 30)
| Parameter | Baseline/pre-treatment | 3-month post CRT | 6-month post-CRT | 12-month post-CRT | 24-month post-CRT | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reference research cohort | D-HNCP CRT Cohort |
| Reference research cohort | D-HNCP CRT Cohort |
| Reference research cohort | D-HNCP CRT Cohort |
| Reference research cohort | D-HNCP CRT Cohort |
| Reference research cohort | D-HNCP CRT Cohort |
| |
| Oral/non-oral Intake | |||||||||||||||
| FOIS 1–5b | 0% | 14% | 0.04 | 50% | 43% | 0.60 | 27% | 21% | 0.75 | 12% | 21% | 0.48 | 0% | 5% | 1.00 |
| PEG in situc | 100% | 91% | 0.14 | 85% | 57% | 0.02 | 38% | 16% | 0.08 | 14% | 3% | 0.20 | 3% | 0% | 1.00 |
| Food category 2–5d | 13% | 19% | 0.75 | 68% | 46% | 0.12 | 39% | 33% | 0.78 | 24% | 17% | 0.73 | 14% | 10% | 1.00 |
| Fluid category 2–5e | 0% | 0% | n/a | 9% | 0% | 0.36 | 9% | 0% | 0.16 | 4% | 0% | 1.00 | 0% | 0% | n/a |
| Oromotor and toxicities | |||||||||||||||
| Oromotor assessmentf | 11% | 17% | 0.72 | 0% | 21% | 0.06 | 5% | 23% | 0.13 | 8% | n/a | n/a | 9% | 0% | n/a |
| Incisal openingg | 50.7 (5.9) | 48.0 (8.8) | 0.13 | 43.2 (8.5) | 48.0 (7.1) | 0.05 | 43.9 (8.5) | 42.8 (12.6) | 0.75 | 46.7 (7.4) | 44.6 (6.9) | 0.36 | 48.6 (8.8) | 48.5 (7.4) | 0.97 |
| Weight (pounds) | 202.6 (44.4) | 190.3 (41) | 0.24 | 173.3 (19.7) | 170.6 (36.7) | 0.77 | 167.4 (24.0) | 174.2 (35.2) | 0.62 | 176.6 (25.4) | 181.8 (33.1) | 0.52 | 179.8 (26.3) | 192.5 (32.9) | 0.20 |
This table percentage for binary outcomes and mean(SD) for continuous outcomes. Bolded values indicate p < 0.05
n/a non/applicable
aFisher’s exact test was used to compare the percentages at each time point (p)
bFunctional oral intake scale (FOIS) [27] expressed as proportion of group receiving a rating of 1-5 indicating more impaired and more restricted diet level
cProportion of group with a percutaneous gastrostomy (PEG) in situ
dProportion of patients managing food consistencies other than normal
eProportion of patients managing fluid consistencies other than normal
fPercentage of patients with total score ≤ 65 indicating impaired function
gIncisal opening actual score measured with Therabite® measuring device in millimeter measurement. Normal ≥ 40
Analysis of Swallow physiology at baseline and 3-month post-chemoradiation therapy patients in the D-HNCP cohort (n = 43) and the reference research sample (n = 30) [25]
| Modified barium swallow parameter | Baseline/pre-treatment | 3 months post-treatment | ||||
|---|---|---|---|---|---|---|
| Research cohort (%) | D-HNCP cohort (%) |
| Research cohort (%) | D-HNCP cohort (%) |
| |
| Oral phase impairmentsa | 10 | 19 | 0.48 | 10 | 6 | 1.0 |
| Pharyngeal phase impairmentsa | 41 | 61 | 0.20 | 42 | 50 | 0.74 |
| Esophageal phase impairmentsa | 36 | 31 | 0.78 | 47 | 38 | 0.73 |
| PAS penetration 2–5b | 10 | 6 | 0.67 | 22 | 6 | 0.34 |
| PAS aspiration 6–8c | 7 | 6 | 1.0 | 0 | 19 | 0.09 |
Fisher’s exact test was used to compare the percentages at each time point (p)
aOral, pharyngeal, and esophageal phase impairments. Percentage of patients with at least one problem
bPenetration–aspiration scale (PAS) [42] penetration: percentage of patients with penetration score of 2–5
cPenetration–aspiration scale (PAS) [42] aspiration: percentage of patients with aspiration score of 6–8, aspirator on thin liquids only